SCHEMBL5770879

SCHEMBL5770879

O=C(O)C(=O)Nc1sc2c(c1C(=O)O)CCN[C@H]2CNC(=O)c1cc2cc(O)ccc2[nH]1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 7/20 0.84
SRC P12931 1/20 0.39
SMAD3 P84022 1/20 0.38
PTPRC P08575 2/20 0.37
PTPN2 P17706 2/20 0.37
PTPRB P23467 1/20 0.35
PTPRE P23469 1/20 0.35
PTPN6 P29350 1/20 0.35
NHERF1 O14745 1/20 0.35
DRD2 P14416 2/20 0.34
DRD3 P35462 2/20 0.34
DRD4 P21917 1/20 0.34
ABL1 P00519 1/20 0.34
PDGFRB P09619 1/20 0.34
KIT P10721 1/20 0.34
BCR P11274 1/20 0.34
FLT3 P36888 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5769138 1.00 PTPN1 (0.84) PTPN1SRCSMAD3PTPRCPTPN2
SCHEMBL5769156 0.91 PTPN1 (1.00) PTPN1PTPRCPTPN2MEN1KMT2A
SCHEMBL5772291 0.90 PTPN1 (0.69) PTPN1SRCDRD2DRD3DRD4
SCHEMBL5768963 0.90 PTPN1 (0.69) PTPN1SRCSMAD3DRD2DRD3
SCHEMBL5767679 0.90 PTPN1 (0.81) PTPN1PTPN2KDM4EHPGDHSD17B10
SCHEMBL5769149 0.90 PTPN1 (0.81) PTPN1PTPN2KDM4EHPGDHSD17B10
SCHEMBL5772314 0.89 PTPN1 (0.79) PTPN1DRD2DRD3DRD4MEN1
SCHEMBL5770079 0.84 PTPN1 (0.60) PTPN1SRCMEN1KMT2AKDM4E
SCHEMBL5797581 0.84 PTPN1 (0.60) PTPN1SRCSMAD3MEN1KMT2A
SCHEMBL5771293 0.81 PTPN1 (0.60) PTPN1PTPRCPTPN2PTPRBPTPRE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1301516-B1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK AS (DK) 2006-03-22 EP disclosed
US-6613903-B2 Such as 7-(benzoylamino-methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno(2,3 -c)pyridine-3-carboxylic acid for treatment of diabetes, insulin resistance, and obesity NOVO NORDISK A/S (DK) 2003-09-02 US disclosed
EP-1301516-A1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) NOVO NORDISK A/S (DK) 2003-04-16 EP disclosed
US-20020151561-A1 Modulators of Protein Tyrosine Phosphatases (PTPases) NOVO NORDISK A/S (DK) 2002-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020151561-A1 Modulators of Protein Tyrosine Phosphatases (PTPases) PTPRO, PTPN1, PTPRS PTPN1 2/4885SRC 243/4885SMAD3 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.